A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
25 March 2026
Read original ↗
🅇 This trial is currently recruiting participants in the UK
Speak to your GP or specialist first. They can help you understand if you might be eligible and what taking part would involve.
🅇 This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE3
Participants
ALL
Age Range
18 Years – 85 Years
About This Trial
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
Who Can Join?
Inclusion Criteria: * Participants must meet all the following criteria to be included in the trial: * Age18 to 85 years. * Participant has a diagnosis of MDD. * Moderate to severe depression at Screening. * Participants have been on a stable dose of antidepressant medication at an adequate dose in the last 4 weeks prior to Screening. * Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening. * Participants with well controlled hypertension. * Participant is able to refrain from smoking during the dosing session. * Participants must use a condom plus spermicide during the trial and for 12 weeks afterwards. Participants of childbearing potential must agree to use a highly effective method of and a negative pregnancy test at Screening and Day -1 prior to dosing. * Participants of non-childbearing potential who are or were capable of producing eggs…
⚠ Always speak to your doctor before applying to any clinical trial.